In a related move, Novartis recently announced a deal involving its subsidiary Sandoz US, which will divest its dermatology and oral solids businesses to Indian pharmaceutical company Aurobindo Pharma for up to $1 billion. This divestiture aligns with Novartis's strategic focus on core growth areas, including radiopharmaceuticals.